Tumor size, as assessed by the total area occupied by cells immunolabelled against human vimentin (hVIM), was significantly reduced in the xenografts derived from the mutant line (18.3%–60.3% vs. 51.8%–71.4%, Figure 1F). Here, VIM is linked to neoplasm.